Abeona Gets RMAT Designation for Epidermolysis Bullosa Gene Therapy – Rare Disease Report
Rare Disease Report |
Abeona Gets RMAT Designation for Epidermolysis Bullosa Gene Therapy
Rare Disease Report This morning, Abeona Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted EB-101, its gene therapy for epidermolysis bullosa (EB), Regenerative Medicine Advanced Therapy (RMAT) designation. In August, the company received … Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in … |
